Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg

• Status: Completed
• Trial end date: 2017-03-10
• Target enrollment: 0
• Participant gender: Male

Summary

A randomized, open-label, multiple dosing, three-way crossover clinical trial to investigate the pharmacokinetic/pharmacodynamic drug-drug interaction of evogliptin 5 mg and pioglitazone 30 mg after oral administration in healthy male subjects

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dong-A ST Co., Ltd.
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• Healthy Male Volunteers (Age: 19~45years)

• 55
• FPG: 70-125 mg/dL

Exclusion Criteria:

• galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption

• Clinically significant Medical History

• Allergy or Drug Hypersensitivity

• AST(SGOT), ALT(SGPT) > Upper Normal Range*1.5, eGFR<80 mL/min

• Drink during clinical trial period

• Smoking during clinical trial period

• Grapefruit/Caffeine intake during clinical trial period

• No Contraception